BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30

$78.30+0.13 (+0.17%)

Close on Nov 13, 2026Market cap $15.25BP/E –Yield –

BridgeBio Pharma EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

BridgeBio Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in BridgeBio Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BBIO.

Revenue growth167.3% · median -0.7%

Gross margin94.3% · median 90.2%

Operating margin-38.5% · median -2.5%

Advertisement
300 × 250

See a number that looks wrong?